Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Merck weighs use of COVID antiviral Lagevrio as Ebola outbreak worsens: report
As governments and health authorities rush to meet the moment of a worsening Ebola outbreak in central Africa, Merck & Co. | As governments and health authorities rush to meet the moment of a worsening Ebola outbreak in central Africa, Merck & Co. is considering dusting off its antiviral molnupiravir, which saw use as a treatment for COVID-19 under an emergency use authorization during the pandemic.
TL;DRAI
Merck is evaluating molnupiravir, its COVID antiviral, for Ebola amid a worsening central Africa outbreak based on animal studies. The approach demonstrates rapid asset repurposing and platform flexibility—a critical advantage when responding to emerging infectious threats.
826 words~4 min read
